MASI Quote, Financials, Valuation and Earnings

Envista Holdings Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of -4.52%. Masimo Corp.'s return on equity of -19.18% beat Envista Holdings Corp.'s return on equity of 0.5%.

Masimo Corp. has a consensus price target of $183.13, signalling upside risk potential of 32.61%. On the other hand Envista Holdings Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 7.58%. Given that Masimo Corp. has higher upside potential than Envista Holdings Corp., analysts believe Masimo Corp. is more attractive than Envista Holdings Corp..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison Envista Holdings Corp. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.453%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Envista Holdings Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Envista Holdings Corp. quarterly revenues of $669.9M. Masimo Corp.'s net income of $53.7M is higher than Envista Holdings Corp.'s net income of -$30.3M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Envista Holdings Corp.'s PE ratio is 244.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.36x versus 1.33x for Envista Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 7.29%. Masimo Corp.'s return on equity of -19.18% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Masimo Corp. has a consensus price target of $183.13, signalling upside risk potential of 32.61%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Masimo Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Masimo Corp. is more attractive than Phibro Animal Health Corp..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Masimo Corp. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo Corp. quarterly revenues are $371.5M, which are larger than Phibro Animal Health Corp. quarterly revenues of $363.9M. Masimo Corp.'s net income of $53.7M is higher than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.36x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 12.4%. Masimo Corp.'s return on equity of -19.18% beat Insulet Corp.'s return on equity of 18.92%.

Masimo Corp. has a consensus price target of $183.13, signalling upside risk potential of 32.61%. On the other hand Insulet Corp. has an analysts' consensus of $378.21 which suggests that it could grow by 22.97%. Given that Masimo Corp. has higher upside potential than Insulet Corp., analysts believe Masimo Corp. is more attractive than Insulet Corp..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Masimo Corp.'s net income of $53.7M is lower than Insulet Corp.'s net income of $87.6M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Insulet Corp.'s PE ratio is 89.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.36x versus 8.83x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 17.41%. Masimo Corp.'s return on equity of -19.18% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Masimo Corp. has a consensus price target of $183.13, signalling upside risk potential of 32.61%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 21.72%. Given that Masimo Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Masimo Corp. is more attractive than West Pharmaceutical Services, Inc..

Masimo Corp. has a beta of 1.262, which suggesting that the stock is 26.208% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. Masimo Corp. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Masimo Corp.'s net income of $53.7M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while West Pharmaceutical Services, Inc.'s PE ratio is 42.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.36x versus 6.86x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.